Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: NTTG who wrote (11523)	9/27/2012 10:40:39 AM
From: Cal Amari	Read Replies (1) \| Respond to of 13111

Not exactly. The basic thresholds for patentability in most jurisdictions are utility, novelty, and inventive step (non-obviousness) based on publicly available prior art - with publicly available prior art not being restricted to prior patents in the jurisdiction of examination. A patent examiner is obliged to compare what is being claimed with the full contents (not just patent claims) of all publicly available prior art (e.g., patents, published patent applications, technical papers, product literature, etc.) - regardless of country of origin of the prior art.